'Cyp2d6 inhibitor' diaporamas de présentation

Increased Risk of Breast Cancer Recurrence in Women Initiating Tamoxifen with CYP2D6 Inhibitors

Increased Risk of Breast Cancer Recurrence in Women Initiating Tamoxifen with CYP2D6 Inhibitors. Aubert RE et al. ASCO 2009; Abstract CRA508. (Oral Presentation). Introduction. Tamoxifen (TAM) is metabolized to its active form, endoxifen, by hepatic cytochrome P450 2D6 (CYP2D6)

434 views • 17 slides